乙型肝炎病毒核心相关抗原的监测及临床意义

刘成; 慕永平; 杨宗国; 陈晓蓉

乙型肝炎病毒核心相关抗原的监测及临床意义

1. 上海市公共卫生临床中心
2. 上海中医药大学附属曙光医院

基金项目:

上海市科学技术委员会医学引导类项目(10411963000)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 3354
- HTML全文浏览量: 21
- PDF下载量: 778
- 被引次数: 0
出版历程
- 出版日期: 2012-10-20

Clinical significance of monitoring hepatitis B virus core-related antigens

Research funding:

摘要

摘要:
监测乙型肝炎病毒核心相关抗原(HBcrAg),能有效预测核苷(酸)类药物抗病毒治疗后产生的病毒学反弹及耐药风险,具有重要的临床实用价值。
- 肝炎核心抗原,乙型 /
- 肝炎病毒,乙型 /
- 肝炎,乙型,慢性
Abstract:
Antiviral nucleot (s) ide analogs are the common therapy for patients with chronic hepatitis B (CHB) infection.HBV DNA in peripheral blood is a sufficient and convenient indicator of treatment response and resistance;however, intrahepatic HBV DNA and covalently closed circular (ccc) DNA are superior indicators of treatment failure at earlier stages.Unfortunately, monitoring of intrahepatic nucleic acids, including HBV DNA, cccDNA and RNA, is complicated and expensive.Since serum levels of hepatitis B virus core-related antigen (HBcrAg) correlate well with intrahepatic levels of HBV cccDNA it may represent an accurate and convenient indicator of treatment response and resistance in CHB patients.In this review, we discuss the recent research efforts to develop strategies for HBcrAg monitoring and to define the underlying mechanisms of this clinical indicator system.Besides its promising clinical value, large-scale dynamic measures of HBcrAg in CHB patients may provide useful insights into the risk and causative factors of resistance to antiviral nucleot (s) analoge therapy.
- hepatitis B core antigens /
- hepatitis B virus /
- hepatitis B

HTML全文

参考文献(29)

[1]European Association for the Study of the Liver.EASL clinicalpractice guidelines:management of chronic hepatitis B[J].J Hepatol, 2009, 50 (2) :227-242.

[2]Lai CL, Ratziu V, Yuen MF, et al.Viral hepatitis B[J].Lan-cet, 2003, 362:2089-2094.

[3] 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].中华肝脏病杂志, 2011, 19 (1) :13-24.

[4] Yuen MF, Wong DK, Sum SS, et al.Effect of lamivudinetherapy on the serum covalently closed circular (ccc) DNAof chronic hepatitis B infection[J].Am J Gastroenterol, 2005, 100 (5) :1099-1103.

[5]Lok AS, McMahon BJ.Chronic hepatitis B:update of rec-ommendations[J].Hepatology, 2004, 39 (3) :857-861.

[6]Rokuhara A, Matsumoto A, Tanaka Y, et al.Hepatitis B vi-rus RNA is measurable in serum and can be a new marker formonitoring lamivudine therapy[J].J Gastroenterol, 2006, 41 (8) :785-790.

[7]Hatakeyama T, Noguchi C, Hiraga N, et al.Serum HBV RNAis a predictor of early emergence of the YMDD mutant in pa-tients treated with lamivudine[J].Hepatology, 2007, 45 (5) :1179-1186.

[8]Usuda S, Okamoto H, Tsuda F, et al.An enzyme-linked im-munosorbent assay with monoclonal antibodies for the determi-nation of phosphorylated hepatitis B core protein (p21c) in ser-um[J].J Virol Methods, 1998, 72 (1) :95-103.

[9]Kimura TA, Rokuhara Y, Sakamoto S, et al.Sensitive en-zyme immunoassay for hepatitis B virus core-related anti-gens and their correlation to virus load[J].J Clin Microbiol, 2002, 40 (2) :439-445.

[10]Suzuki F, Miyakoshi H, Kobayashi M, et al.Correlation be-tween serum hepatitis B virus core-related antigen and in-trahepatic covalently closed circular DNA in chronic hepatitisB patients[J].J M Virol, 2009, 81 (1) :27-33.

[11]Kimura T, Ohno N, Terada N, et al.Hepatitis B virus DNA-negative Dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich do-main[J].J Biol Chem, 2005, 280 (23) :21713-21719.

[12]Rokuhara A, Tanaka E, Matsumoto A, et al.Clinical evalua-tion of a new enzyme immunoassay for hepatitis B virus core-related antigen;a marker distinct from viral DNA for moni-toring lamivudine treatment[J].J Viral Hepatol, 2003, 10 (4) :324-330.

[13]Sung JJY, Wong ML, Bowden S, et al.Intrahepatic hepati-tis B virus covalently closed circular DNA can be a predictorof sustained response to therapy[J].Gastroenterology, 2005, 128 (7) :1890-1897.

[14]Wong DK, Tanaka Y, Lai CL, et al.Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis Binfection[J].J Clin Microbiol, 2007, 45 (12) :3942-3947.

[15]Wong DK, Tanaka Y, Lai CL, et al.Detection of hepatitis Bvirus core-related antigens as a marker for the monitoring ofviral activity during nucleoside analogue therapy[J].J Hepa-tol, 2006, 44 (suppl 2) :S192-S192.

[16]Wong DK, Yuen MF, Tanaka Y, et al.Correlation betweenhepatitis B virus core-related antigens and intrahepatic cova-lently closed circular DNA levels[J].Hepatology, 2005, 42 (4) :712A.

[17]Rokuhara A, Sun XH, Tanaka E, et al.Hepatitis B virus coreand core-related antigen quantitation in Chinese patientswith chronic genotype B and C hepatitis B virus infection[J].J Gastroen Hepatol, 2005, 20 (11) :1726-1730.

[18]Rokuhara A, Tanaka E, Matsumoto A, et al.Clinical evalua-tion of a new enzyme immunoassay for hepatitis B virus core-related antigen:a marker distinct from viral DNA for moni-toring lamivudine treatment[J].J Viral Hepatitis, 2003, 10 (4) :324-330.

[19]Marzano A, Gaia S, Ghisetti V, et al.Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence.Liver transpl, 2005, 11 (4) :402-409.

[20]Werle-Lapostolle B, Bowden S, Locarnini S, et al.Persist-ence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy[J].Gastroen-terology, 2004, 126 (7) :1750-1758.

[21]Hamada R, Nakao R, Hai N, et al.Hepatitis B virus core-related antigen as an indicator of safe discontinuation of lami-vudine therapy[J].Hepatology, 2006, 44 (4) :562A.

[22]Matsumoto A, Tanaka E, Suzuki Y, et al.Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos (t) ide analogs in patients with chronic hepatitis B[J].Hepatol Res, 2012, 42 (2) :139-149.

[23]Tanaka E, Matsumoto A, Suzuki F, et al.Measurement of hepatitis B virus core-related antigen is valuable for identif-ying patients who are at low risk of lamivudine resistance[J].Liver Int, 2006, 26 (1) :90-96.

[24]Tanaka E, Matsumoto A, Yoshizawa K, et al.Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy[J].Intervirology, 2008, 51 (Suppl1) :3-6.

[25]Shinkai N, Tanaka Y, Orito E, et al.Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus in-fection[J].Hepatol Res, 2006, 36 (4) :272-276.

[26]Matsumoto A, Tanaka E, Minami M, et al.Low serum level of hepatitis B indicates unlikely reactivation core-related an-tigen of hepatitis after cessation of lamivudine therapy[J].Hepatol Res, 2007, 37 (8) :661-666.

[27]Fujimoto M, Ichikawa T, Nakao K, et al.The significance of enzyme immunoassay for the assessment of hepatitis B virus core-related antigen following liver transplantation[J].Inter Med, 2009, 48 (18) :1577-1583.

[28]Matsuzaki T, Ichikawa T, Otani M, et al.The significance of hepatitis B virus core-related antigen and covalently closed circular DNA as HBV-refection markers after liver transplan-tation[J].J Hepatol, 2010, 52 (Suppl1) :S183-S317.

[29]Hosaka T, Suzuki F, Kobayashi M, et al.HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma dur-ing antiviral therapy[J].Liver Int, 2010, 30 (10) :1461-1470.

施引文献

资源附件(0)

访问统计